Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC

June 11th 2025

Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.

Dr Pennell on the Significance of the FDA Approval of Taletrectinib for ROS1+ NSCLC

June 11th 2025

Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.

Dr Zhang on Sacituzumab Tirumotecan in Pretreated Advanced EGFR-Mutated NSCLC

June 11th 2025

Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.

FDA Approves Taletrectinib for ROS1+ Advanced NSCLC

June 11th 2025

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.

Sacituzumab Tirumotecan Plus Tagitanlimab Receives Breakthrough Therapy Designation in China for First-Line, Nonsquamous NSCLC

June 11th 2025

China’s Center for Drug Evaluation granted breakthrough therapy designation to sacituzumab tirumotecan for nonsquamous non–small cell lung cancer.

First-Line Lurbinectedin Plus Atezolizumab Maintenance Under Priority Review for ES-SCLC

June 10th 2025

The FDA granted priority review to the sNDA seeking the approval of the first-line maintenance combination of lurbinectedin and atezolizumab for ES-SCLC.

Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List

June 9th 2025

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

Five Under 5: Top Oncology Videos for the Week of 6/1

June 8th 2025

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

RET Inhibitor Rechallenge Demonstrates Activity in Previously Treated NSCLC

June 8th 2025

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Advancements in the Management of Stage III NSCLC: Expert Insights on the LAURA Trial

June 5th 2025

Panelists discuss how targeted therapy with osimertinib has revolutionized treatment approaches for unresectable early-stage non–small cell lung cancer (NSCLC) patients with EGFR mutations, offering new hope for a previously underserved patient population.

Multidisciplinary Perspectives In the Management of Borderline Resectable Early-Stage NSCLC: A Focus on the Role of Pulmonary Rehabilitation

June 5th 2025

Panelists discuss how PD-L1 expression levels significantly impact treatment decisions in unresectable early-stage non–small cell lung cancer (NSCLC), with consensus that biomarker status should be evaluated before finalizing treatment approaches.

THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC

June 4th 2025

THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.

BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma

June 4th 2025

Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.

Multidisciplinary Collaboration Is Essential in Early-Stage NSCLC

June 4th 2025

In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.

Dr Preeshagul on Emerging Treatments in SCLC

June 3rd 2025

Isabel Preeshagul, DO, MBS, highlights the role of emerging therapies in the SCLC landscape, including tarlatamab and durvalumab.

Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC

June 3rd 2025

Jacob Sands, MD, presents promising early-phase trial results for obrixtamig, a novel DLL3-targeting T-cell engager, in patients with large cell neuroendocrine carcinoma of the lung (LCNEC-L), shared at ESMO Congress 2024.

Consolidation Benmelstobart ± Anlotinib Provides Substantial PFS Benefits in Stage III NSCLC

June 3rd 2025

Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC

June 3rd 2025

Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.

Dellphi-304 Data Reinforce Role of Tarlatamab as Second-Line SOC in Small Cell Lung Cancer

June 3rd 2025

Tarlatamab improved overall survival and progression-free survival in the second-line treatment of small cell lung cancer.

Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC

June 3rd 2025

Neoadjuvant osimertinib as monotherapy or plus chemotherapy was more effective vs chemotherapy alone in patients with resectable EGFR-mutated NSCLC.